Research Blogs

April 30, 2024

Leveraging Basic Science to Stop Drug Resistance in RET+ Lung Cancer

Read time: 4 minutes Advances in targeted therapies have allowed us to treat some types of lung cancer with mutations in specific genes (for example, EGFR, KRAS, and RET). This has

READ MORE about Leveraging Basic Science to Stop Drug Resistance in RET+ Lung Cancer›
April 25, 2024

Highlights of AACR 2024: Where the Laboratory Meets the Patient

Research and treatment updates from the 2024 American Association for Cancer Research meeting—NSCLC, SCLC, ALK, EGFR, RET, KRAS, MET, Immunotherapy.

READ MORE about Highlights of AACR 2024: Where the Laboratory Meets the Patient›
April 02, 2024

Working to Diagnose Lung Cancer Earlier in Hispanic Communities

Read time: 4 minutes Lung cancer screening guidelines were first issued by the United States Preventive Services Task Force in 2013 to help doctors find lung cancer in its earliest

READ MORE about Working to Diagnose Lung Cancer Earlier in Hispanic Communities›
March 26, 2024

Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer

An update on our work investigating cachexia as well as the announcement of five new Cancer Grand Challenge teams and their projects.

READ MORE about Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer›
March 19, 2024

Leveraging Genetics to Understand Why Younger Adults Are Developing Lung Cancer

New research is looking into why so many young adults are being diagnosed with lung cancer and if there is a genetic component increasing their risk.

READ MORE about Leveraging Genetics to Understand Why Younger Adults Are Developing Lung Cancer›
March 05, 2024

From Leukemia to ALK+ NSCLC: Finding a New Way to Overcome Drug Resistance

Read Time: 5 minutes Approximately 4% of patients diagnosed with non-small cell lung cancer (NSCLC) will have their tumors test positive for an ALK biomarker. This means the ALK

READ MORE about From Leukemia to ALK+ NSCLC: Finding a New Way to Overcome Drug Resistance›
February 20, 2024

Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer

Approximately 10%-15% of patients with non-small cell lung cancer have tumors with mutations in the EGFR (epidermal growth factor receptor) gene. EGFR mutations are known to drive

READ MORE about Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer›
January 23, 2024

Top 5 Most Popular Blogs from 2023

LUNGevity blogs share personal stories, research updates, scientific meeting takeaways, policy news, and much more. Joining our Email List will help you stay updated on these

READ MORE about Top 5 Most Popular Blogs from 2023›
December 12, 2023

Creating a Best Practices Roadmap for Lung Cancer Screening Implementation

Finding lung cancer in its early stages significantly increases the chance of successfully treating and even curing the disease. Low-dose CT is the current approved approach to

READ MORE about Creating a Best Practices Roadmap for Lung Cancer Screening Implementation›
December 05, 2023

Building a Computational Model to Optimize Patient Treatment

Approximately 20%-35% of patients newly diagnosed with non-small cell lung cancer (NSCLC) will have locally advanced disease, sometimes referred to as stage III NSCLC. The

READ MORE about Building a Computational Model to Optimize Patient Treatment›
November 14, 2023

Treatment & Research Takeaways: ESMO 2023 Meeting

The European Society for Medical Oncology (ESMO) recently held its annual conference from October 20 – 24, 2023 in Madrid, Spain. ESMO represents one of the largest gatherings of

READ MORE about Treatment & Research Takeaways: ESMO 2023 Meeting›
November 07, 2023

Innovative Therapeutic Vaccine for ALK+ NSCLC Heads to Phase 1 Clinical Trial

Different types of lung cancer are known to be caused, or driven, by alterations in genes such as EGFR or ALK. One such alteration, the fusion of the ALK gene with another gene

READ MORE about Innovative Therapeutic Vaccine for ALK+ NSCLC Heads to Phase 1 Clinical Trial›